Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
Tissue Cell
; 61: 109-114, 2019 Dec.
Article
em En
| MEDLINE
| ID: mdl-31759402
ABSTRACT
The aim of this study was to determine the efficacy of oral recombinant methioninase (o-rMETase) on a model of colon cancer growing on the peritoneal surface using a patients-derived orthotopic xenograft (PDOX) nude mouse model. Forty PDOX mouse models with colon cancer growing on the peritoneum were divided into 4 groups of 10 mice each by measuring the tumor size and fluorescence intensity untreated control; 5-fluorouracil (5-FU) (50â¯mg/kg, once a week for two weeks, ip) and oxaliplatinum (OXA) (6⯠mg/kg, once a week for two weeks, ip); o-rMETase (100 units/day, oral 14 consecutive days); combination 5-FUâ¯+â¯OXA and o-rMETase. All treatments inhibited tumor growth compared to the untreated control. The combination of 5-FUâ¯+â¯OXA plus o-rMETase was significantly more efficacious than the control and each drug alone and was the only treatment that caused tumor regression. The present study is the first demonstrating the efficacy of o-rMETase combination therapy on a PDOX model of peritoneal colon cancer, suggesting potential clinical development of o-rMETase in a recalcitrant cancer.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Peritônio
/
Platina
/
Liases de Carbono-Enxofre
/
Proteínas Recombinantes
/
Neoplasias do Colo
/
Ensaios Antitumorais Modelo de Xenoenxerto
/
Fluoruracila
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article